The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer

AKR1C3 is a novel therapeutic target in castration-resistant prostate cancer (CRPC) and estrogen receptor (ER)-positive breast cancer because of its ability to produce testosterone and 17β-estradiol intratumorally, thus promoting nuclear receptor signaling and tumor progression. A panel of CRPC, ER-...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Yarong Diana, Fu, Melissa, Brooke, Darby G., Heinrich, Daniel M., Denny, William A., Jamieson, Stephen M. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061482/
https://www.ncbi.nlm.nih.gov/pubmed/24995161
http://dx.doi.org/10.3389/fonc.2014.00159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4061482/
https://www.ncbi.nlm.nih.gov/pubmed/24995161
http://dx.doi.org/10.3389/fonc.2014.00159

Ejemplares similares